Form 4: Merck Director Douglas M. Baker Jr. Reports Acquisition of Phantom Stock Units Under 10b5-1 Plan

Merck & Co., Inc. Director Douglas M. Baker Jr. reported the acquisition of 2,863.0921 phantom stock units as part of a pre-scheduled 10b5-1 plan, effective May 30, 2025, alongside a direct holding of 16,000 common shares.

Summary

• Douglas M. Baker Jr., a Director of Merck & Co., Inc. (MRK), filed a Form 4 reporting changes in beneficial ownership.
• The filing indicates that the reported transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), suggesting a pre-scheduled transaction.
• Mr. Baker directly beneficially owns 16,000 shares of Merck & Co., Inc. Common Stock.
• On May 30, 2025, Mr. Baker acquired 2,863.0921 phantom stock units.
• These phantom stock units are convertible on a 1-for-1 basis into Common Stock and were acquired at a price of $76.84 per unit.
• Following this transaction, Mr. Baker beneficially owns a total of 9,343.5277 phantom stock units.
• The phantom stock units are to be settled 100% in cash upon termination of service, as per the Plan for Deferred Payment of Directors' Compensation.
• The reported holdings of phantom stock units include units acquired through dividend reinvestment transactions.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The acquisition of phantom stock units by a director is a routine compensation event and indicates continued alignment, but the cash settlement aspect means no direct equity increase. It's not a strong signal for stock performance.

Positives

• The acquisition of additional phantom stock units by a director, as part of a pre-scheduled 10b5-1 plan, indicates continued alignment of interests with shareholders and a structured approach to executive incentives.
• The phantom stock units are part of a deferred compensation plan, which can aid in long-term retention of key personnel.

Negatives

• The phantom stock units are cash-settled, meaning they do not directly increase the director's equity stake in the company's common stock, but rather represent a cash obligation for the company upon settlement.

Future Outlook

The filing indicates future settlement of phantom stock units in cash upon the reporting person's termination of service, in accordance with a pre-elected distribution schedule under the Plan for Deferred Payment of Directors' Compensation.

Management Comments

• The phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies. The use of phantom stock units as part of director compensation is a standard practice in the pharmaceutical and broader corporate sectors, aligning director interests with company performance without immediate equity dilution.

Comparison to Industry Standards

• The compensation structure involving phantom stock units settled in cash is a common deferred compensation mechanism for directors in large pharmaceutical companies like Pfizer, Johnson & Johnson, and Bristol Myers Squibb, aiming to retain talent and align long-term interests.
• The specific value of the units acquired ($76.84) reflects the company's stock price at the time of acquisition, which is standard for such plans.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by a director aligns their interests with long-term company performance, potentially fostering better governance. However, the cash settlement means no direct equity dilution from these specific units.
• Employees: Not directly impacted by this director compensation filing.

Next Steps

• Settlement of phantom stock units in cash upon the reporting person's termination of service, as per the deferred compensation plan.

Key Dates

Recommendation

Keywords

Merck & Co., MRK, SEC Form 4, Insider Transaction, Beneficial Ownership, Phantom Stock, Director Compensation, Rule 10b5-1 Plan, Equity Holdings